# A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma

> **NCT05917158** · PHASE2 · RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma
- Upper Tract Urothelial Carcinoma
- UTUC

## Interventions

- **DRUG:** RC48-ADC and JS001

## Key facts

- **NCT ID:** NCT05917158
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-23
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917158, "A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05917158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*